Nausea on Ozempic, Wegovy, Mounjaro or Zepbound: when it peaks and what helps
Reviewed 11 sourcesPublished by PepVault
Nausea on Ozempic, Wegovy, Mounjaro and Zepbound: each label's rate by dose against placebo, the week it peaks, how long a bout lasts and what helps.

- Last reviewed
- Sources
- 11
- Questions
- 8
- Compounds
- 3
The short answer
Nausea is the most common side effect of all four. In the weight trials it hit 44% on Wegovy 2.4 mg and 25% to 29% on Zepbound, against 16% and 8% on placebo. On semaglutide it peaked around week 20, just after the dose climb, and a bout lasted a median of 8 days. Small, plain, low-fat meals, eaten slowly, and steady sips of fluid help.
Evidence: FDA prescribing information for all four medicines, built on randomized placebo-controlled trials in people; trial registry results from STEP 1, SURMOUNT-1 and SURMOUNT-5; two sponsor-funded analyses of the trials after the fact for timing and duration; an expert consensus and a joint society advisory for the eating advice.

How common is nausea on Ozempic, Wegovy, Mounjaro and Zepbound?
The most common side effect on all four. Ozempic and Wegovy are semaglutide; Mounjaro and Zepbound are tirzepatide. Each US label counts the share of people in its placebo-controlled trials who reported nausea or vomiting at least once, beside a placebo group on a dummy shot1234:
| Medicine and dose | Trials behind the number | Nausea: drug / placebo | Vomiting: drug / placebo |
|---|---|---|---|
| Ozempic 0.5 mg | 2 type 2 diabetes trials, 32.9 weeks on average | 15.8% / 6.1% | 5% / 2.3% |
| Ozempic 1 mg | The same 2 trials | 20.3% / 6.1% | 9.2% / 2.3% |
| Mounjaro 5 mg | 2 type 2 diabetes trials, 36.6 weeks on average | 12% / 4% | 5% / 2% |
| Mounjaro 10 mg | The same 2 trials | 15% / 4% | 5% / 2% |
| Mounjaro 15 mg | The same 2 trials | 18% / 4% | 9% / 2% |
| Wegovy 2.4 mg | 3 weight trials, up to 68 weeks | 44% / 16% | 24% / 6% |
| Wegovy 7.2 mg | 2 weight trials, 72 weeks | 39% / 13% | 22% / 6% |
| Zepbound 5 mg | 2 weight trials, up to 72 weeks | 25% / 8% | 8% / 2% |
| Zepbound 10 mg | The same 2 trials | 29% / 8% | 11% / 2% |
| Zepbound 15 mg | The same 2 trials | 28% / 8% | 13% / 2% |
The gap between drug and placebo is the part the medicine adds. The weight doses bring more nausea than the diabetes doses, and the labels warn that rates from different trials cannot be compared directly13. In the 7.2 mg trials, the 2.4 mg group reported nausea at 35%2. When both drugs ran in one 72-week trial (SURMOUNT-5) at their top weight doses or the highest tolerated, nausea was a tie, 43.6% on tirzepatide and 44.4% on semaglutide, while vomiting was lower on tirzepatide, 15.0% against 21.3%11.
In teenagers aged 12 and older on Wegovy 2.4 mg, nausea affected 42% against 18% on placebo, and vomiting 36% against 10%2.

When does GLP-1 nausea peak?
During and just after the dose climb, called titration: the step-up from a low starting dose every four weeks or more. All four labels say most nausea, vomiting and diarrhea came while the dose was rising, and the Mounjaro and Zepbound labels add that it decreased over time1234.
| Weeks on semaglutide 2.4 mg (STEP 1 to 3) | Dose | What the trials saw |
|---|---|---|
| 1 to 16 | 0.25, 0.5, 1 and 1.7 mg, four weeks each | Most people who had a stomach side effect had their first one during the climb5. |
| 17 | 2.4 mg | The climb reaches the full dose2. |
| About 20 | 2.4 mg | The share of people with nausea at any one time peaks; after week 20, few have a first stomach side effect5. |
| 20 to 68 | 2.4 mg | Nausea falls the most of any stomach effect, while staying above placebo5. |
On tirzepatide the climb is longer: 2.5 mg for four weeks, then 2.5 mg more every four weeks or more, so 15 mg arrives at week 20 at the earliest4. The pattern is the same. In SURMOUNT-1 to -3, people who needed an anti-nausea medicine most often took their first one in the first 24 weeks, the stretch that held the climb6. An expert panel puts the most nausea in the first four to five weeks, when stomach emptying slows the most7.
PepVault's dose log keeps each weekly shot with its date and the step-ups your prescriber set, as you enter them, so a queasy week can be matched to the step before it. Log it in PepVault
Which day after the shot is nausea worst?
No trial we found counted nausea by day of the week; what is known is how the drugs move through the blood. Semaglutide reaches its highest level 1 to 3 days after a shot; tirzepatide reaches its peak after a median of 24 hours, anywhere from 8 to 72 hours24.
A 2025 advisory from four US obesity and nutrition societies says nausea often comes in the morning or after a long stretch without food, and that some people get caught in a loop: they skip food because they feel sick, which makes the nausea worse8.
Commonly reported: queasiness worst in the first one to three days after the shot and in the weeks after a step-up, easing by the next dose. Nausea or an upset stomach was mentioned by 14 of 41 people on semaglutide and 9 of 77 on tirzepatide in the open write-ups counted on our reports pages.
How long does nausea last on a GLP-1?
About a week per bout. In the pooled STEP 1 to 3 trials each episode was timed from start to end: the median, the middle value, was 8 days for nausea and 2 days for vomiting on semaglutide 2.4 mg, similar to placebo5. The trial registries count every bout reported, so we divided those counts by the number of people who had any91011:
| Trial and group | People with nausea | Bouts reported | Bouts per person who had it (our division) |
|---|---|---|---|
| STEP 1, semaglutide 2.4 mg (to week 75) | 576 of 1,306 (44.1%) | 1,067 | 1.9 |
| STEP 1, placebo | 114 of 655 (17.4%) | 146 | 1.3 |
| SURMOUNT-1, tirzepatide 5 mg (up to 193 weeks) | 160 of 630 (25.4%) | 404 | 2.5 |
| SURMOUNT-1, tirzepatide 10 mg | 217 of 636 (34.1%) | 540 | 2.5 |
| SURMOUNT-1, tirzepatide 15 mg | 201 of 630 (31.9%) | 506 | 2.5 |
| SURMOUNT-1, placebo | 63 of 643 (9.8%) | 103 | 1.6 |
| SURMOUNT-5, tirzepatide (72 weeks) | 163 of 374 (43.6%) | 561 | 3.4 |
| SURMOUNT-5, semaglutide | 167 of 376 (44.4%) | 505 | 3.0 |
So people who felt sick had two to three bouts on average over a year or more, against 1.3 to 1.6 on placebo, each lasting days. Read each trial on its own: SURMOUNT-1's count runs to week 193, and SURMOUNT-5 was open-label, so everyone knew which drug they took1011. After the climb it keeps easing: in STEP 4, people who reached 2.4 mg by week 20 and stayed on it saw nausea fall over the next 48 weeks, and only two stopped for a stomach effect after week 205. No primary source we found gives a per-bout length for tirzepatide.
Why do GLP-1s make you nauseous?
Two things at once. GLP-1 medicines slow stomach emptying, so food sits longer, and all four labels state that effect1234. They also act on the brain: the STEP analysis's authors write that GLP-1 nausea may come mainly from the brain, because in animal studies the nausea from GLP-1 shots runs through GLP-1 receptors in the central nervous system5. That part is an animal finding.
Nausea is not the engine of the weight loss. Of the extra weight lost on semaglutide 2.4 mg over placebo, under one percentage point was explained by stomach side effects5. For tirzepatide, nausea, vomiting, diarrhea and indigestion together accounted for up to 3.1% of the weight lost, and people with nausea lost slightly more, not less: 22.0% against 19.7% in SURMOUNT-16. A settled stomach does not mean the dose has stopped working.
Is nausea on a GLP-1 serious?
Almost never. In STEP 1 to 3, 98.1% of all stomach side effects on semaglutide 2.4 mg were mild or moderate and 99.5% were not serious5. In STEP 1, one person of 1,306 on semaglutide had nausea counted as a serious event, and four had vomiting9. Few stopped: on Wegovy, 1.8% left over nausea and 1.2% over vomiting, against 0.2% and 0% on placebo2. More often the dose was adjusted: 12.5% on semaglutide lowered or paused it for a stomach effect, against 1.7% on placebo5.
The real risk is fluid. All four labels note that kidney injury has been reported after approval, mostly in people whose nausea, vomiting or diarrhea dried them out, and they ask people to drink enough1234.
What helps with nausea on a GLP-1?
Small, plain meals and steady fluids. The steps below come from the expert panel's list for nausea and vomiting, the nutrition advisory and the trials' own counselling678:
- Eat a small breakfast, then small meals every three to four hours, so your stomach is never empty for long and never overfull.
- Eat slowly, and stop at the first sign of fullness, even with food left on the plate.
- Choose bland, low-fat food cooked by baking, grilling or boiling; skip fried food, rich sauces and very sweet meals.
- Keep crackers, apples, mint or ginger at hand; ginger or peppermint tea, and acupressure wristbands, help some people.
- Sip clear, cool drinks through the day, and if nausea lingers, drink 30 to 60 minutes before or after a meal rather than with it.
- Stay upright after eating, avoid strong smells, and get some fresh air or a light walk.
- Keep alcohol to a minimum: the advisory says it can worsen nausea and reflux.
If that is not enough, the dose and a medicine are your prescriber's levers. The Wegovy shot's label tells prescribers to consider waiting four more weeks before the next step if a dose is not tolerated2. Anti-nausea medicines were common: 13.8% to 27.5% of people on tirzepatide in SURMOUNT-1 to -3 used one, against 5.8% to 6.7% on placebo6. The advisory notes that some, such as prochlorperazine, may suit better than ondansetron, which can worsen constipation8, and the panel suggests a lower dose if one is still needed a month after reaching the full dose7. None of these is approved for GLP-1 nausea itself; our guide to tradipitant covers the one with a phase 3 result.
When to get help Tell your prescriber promptly about nausea or vomiting that is severe or will not go away; stop the shot and call right away for severe pain in your stomach area that will not go away, with or without vomiting, as the labels ask1234.
How do I keep track of nausea on a GLP-1?
Note the day it starts, how strong it is, what you ate and your dose. A few weeks of notes show whether it fades after each step-up, as in the trials, or keeps going, the pattern to bring to your prescriber.
PepVault's side-effect log records each symptom with the compound, a severity from minimal to very severe, the date and a note. Nausea is one tap in the quick list. Log it in PepVault
Diarrhea, constipation and heartburn on a GLP-1 have their own guides.
Sources
- OZEMPIC (semaglutide) injection prescribing information, DailyMed (SPL version 20; published on DailyMed June 10, 2026). Sections 5.6, 6.1 (Table 1), 12.3, 17 and the Medication Guide. dailymed.nlm.nih.gov
- WEGOVY (semaglutide) injection and tablets prescribing information, DailyMed (SPL version 19; published on DailyMed June 30, 2026). Sections 2.2, 5, 6.1 (Tables 3, 4 and 5), 12.3, 17 and the Medication Guide. dailymed.nlm.nih.gov
- MOUNJARO (tirzepatide) injection prescribing information, DailyMed (SPL version 40; published on DailyMed September 2, 2026). Sections 5, 6.1 (Table 1), 12.3, 17 and the Medication Guide. dailymed.nlm.nih.gov
- ZEPBOUND (tirzepatide) injection prescribing information, DailyMed (SPL version 40; published on DailyMed September 2, 2026). Sections 2, 5, 6.1 (Table 1), 12.3, 17 and the Medication Guide. dailymed.nlm.nih.gov
- Wharton S et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24:94-105. PubMed 34514682
- Rubino DM et al. Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. Diabetes Obes Metab. 2025;27:1826-1835. PubMed 39789843
- Gorgojo-Martínez JJ et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2023;12:145. PubMed 36614945
- Mozaffarian D et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society. Obesity (Silver Spring). 2025;33(8):1475-1503. PubMed 40445127
- ClinicalTrials.gov NCT03548935 (STEP 1; sponsor Novo Nordisk A/S). Results: adverse events, week 0 to 75. clinicaltrials.gov
- ClinicalTrials.gov NCT04184622 (SURMOUNT-1; sponsor Eli Lilly and Company). Results: adverse events, baseline up to week 193. clinicaltrials.gov
- ClinicalTrials.gov NCT05822830 (SURMOUNT-5; sponsor Eli Lilly and Company). Results: adverse events, baseline up to week 72. clinicaltrials.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.